Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SUMMER INFAN | SUMR | 9.94% |
| SCIENTIFIC L | SCIL | 8.00% |
| NEW ORIENTAL | EDU | 5.80% |
| FEDERAL MOGU | FDML | 5.80% |
| NATUS MEDICA | BABY | 5.69% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
DR Horton, Inc. ( DHI - Analyst Report ) , one of the largest homebuilding companies in the U.S, announced the acquisition of the homebuilding business of Breland Homes, another U.S. homebuilder. With the acquisition, DR Horton will add 320 high quality homes and 1,020 finished lots to its inventory.
DR Horton has exhibited solid performance through the first three quarters of fiscal 2012, driven by its strategy of expanding operations through capital investments, maintaining inventory levels, optimizing gross margins, and restricting selling, general and administrative (SG&A) expenses and interest costs effectively. As a result, growth in high single to double digits was observed in net sales orders, homes sales closed and sales order backlog through the first three quarters of fiscal 2012.
DR Horton has been performing well by offering high quality homes with sales prices ranging from $90,000 to over $600,000. As the average sales price of these newly- acquired homes is $200,000, these fall well within the company’s pricing range.
Improved market conditions in the Midwest, Southwest and Southeast regions have accelerated DR Horton’s growth. Breland Homes, on the other hand, primarily operates in Huntsville, Mobile and Baldwin County in Alabama and along the gulf coast of Mississippi. This acquisition is expected to bolster DR Horton’s position in the highly lucrative housing market in the Southeastern region of United States
Outlook
The company expects profitability in the fourth quarter of fiscal 2012 and fiscal 2013. The company is well positioned with its strong balance sheet and liquidity and intends to further expand its business in fiscal 2013.
We currently have a Neutral recommendation on DR Horton. The stock carries a Zacks #2 Rank (a short-term ‘Buy’ rating).
We appreciate the company’s strong position and believe that the company will benefit from the recovering market conditions. However, home price appreciation is limited and there is still oversupply in the housing market.
Read the full reports :
Analyst Report on DHI